Analyst Observations
Published: October 28, 2025
This content is for informational purposes only. This should not be construed as solicitation. The general public should consult their financial advisor for additional information related to investment decisions.
Comments include: DHI, NVDA, RCL, & UHS.

 

DHI D.R. Horton, Inc. ($153.80) - Building - DHI broke a triple bottom at $148 to return to a sell signal and violate the bullish support line. The stock will drop to a 3 for 5'er with the trendline violation and the stock resides on the threshold of falling into the bottom half of the Building sector matrix. From here, support lies at $142, while additional can be found at $130.
NVDA NVIDIA Corporation ($202.67) - Semiconductors - NVDA gained over 5% intraday Tuesday to reach a new all-time high at $200. This 4 for 5'er continues to demonstrate favorable long-term technical characteristics, as it has maintained an RS buy signal against the market since 2023 and has been in a positive trend since May. While the recent improvement is favorable, the stock is nearing extended territory again. Current holders should not be concerned. Those looking to add exposure may be best served easing in or waiting for potential normalization of the trading band. Initial support can be seen at $178. Note that earnings are expected on 11/19.
RCL Royal Caribbean Cruises Ltd. ($292.42) - Leisure - RCL broke a double bottom at $296 to return to a sell signal and violate support at $300 dating back to August. The notable downside move on 10/28 will bring both the peer and market RS charts back into Os, dropping the stock down to a 3 for 5'er trading in a positive trend. From here support lies in the $250 range, while additional can be found at $236.
UHS Universal Health Services, Inc. ($218.47) - Healthcare - UHS inched higher to complete a double top break at $216, marking its fourth consecutive buy signal. The 4 for 5'er shifted up from a 3 last month after reversing back into Xs against the market. Additionally, the stock ranks in the top third of the healthcare sector matrix. The weekly OBOS indicates that the stock is in overbought territory, so wait for the 10-week trading band to normalize before considering. Initial support is at $196, with additional support at $186.
Back to report

DISCLOSURE

This report is for Internal Use Only and not for distribution to the public. While we make every effort to be free of errors in this report, it contains data obtained from other sources. We believe these sources to be reliable, but we cannot guarantee their accuracy. Investors who use options should read the Options Disclosure Document before making any particular investment decision. Officers or employees of this firm may now or in the future have a position in the stocks mentioned in this report. Dorsey, Wright is a Registered Investment Advisor with the U.S. Securities & Exchange Commission. Copies of Form ADV Part II are available upon request.
Equity prices provided by Thomson-Reuters. Cross Rate prices provided by Tenfore Systems. Option prices provided by OPRA
Copyright © 1995-{ENDYEAR} Dorsey, Wright & Associates, LLC.®
All quotes displayed are delayed 20 minutes
Disclaimer/Terms of Use/Copyright